Search
for
Sort by
Research 691–720 of 877
- A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
- Overview of Alopecia Areata
- Hox in hair growth and development
- Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines☆
- Metabolites from Macroalgae and Its Applications in the Cosmetic Industry: A Circular Economy Approach
- The Role of Interferon-γ in Autoimmune Polyendocrine Syndrome Type 1
- Exploring the new horizons of drug repurposing: A vital tool for turning hard work into smart work
- A Review of Adverse Cutaneous Drug Reactions Resulting from the Use of Interferon and Ribavirin
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
- Alopecia areata: What’s new in epidemiology, pathogenesis, diagnosis, and therapeutic options?
- Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata
- Role of janus kinase inhibitors in the treatment of alopecia areata
- All hairstyles are not created equal: What the dermatologist needs to know about black hairstyling practices and the risk of traction alopecia (TA)
- Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata
- Treatment of pediatric alopecia areata: A systematic review
- Poliosis circumscripta: Overview and underlying causes
- Assessment of Quality of Life and Treatment Outcomes of Patients With Persistent Postchemotherapy Alopecia
- A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata
- Frontal fibrosing alopecia: An update on the hypothesis of pathogenesis and treatment
- The efficacy and safety of JAK inhibitors for alopecia areata: A systematic review and meta-analysis of prospective studies
- Latanoprost Loaded in Polymeric Nanocapsules for Effective Topical Treatment of Alopecia
- “‘You lose your hair, what’s the big deal?’ I was so embarrassed, I was so self-conscious, I was so depressed:” a qualitative interview study to understand the psychosocial burden of alopecia areata
- Eyebrow Loss
- Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: A pooled analysis
- Prevention and Treatment of Chemotherapy-Induced Alopecia
- Treatments for alopecia areata: A systematic review and network meta‐analysis
- Expanding phenotype of hereditary fibrosing poikiloderma with tendon contractures, myopathy, and pulmonary fibrosis caused by FAM111B mutations: Report of an additional family raising the question of cancer predisposition and a short review of early-onset poikiloderma
- British Association of Dermatologists living guideline for managing people with alopecia areata 2024
- Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
- Delivery systems in nanocosmeceuticals